EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio's Inhibitor of Complement Component 5 (C5) and EyePoint's Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic AtrophyBusiness Wire • 02/27/23
Rallybio Announces Appointment of Jonathan I. Lieber as Chief Financial OfficerBusiness Wire • 01/31/23
Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2023Business Wire • 01/05/23
Rallybio Announces Publication of Data Highlighting the Ability of HPA-1a-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAITBusiness Wire • 12/15/22
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare DiseasesBusiness Wire • 12/01/22
Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5Business Wire • 11/07/22
Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune ThrombocytopeniaBusiness Wire • 09/28/22
Rallybio Announces In-Licensing of Potential First-In-Class Preclinical Antibody Candidate from SanofiBusiness Wire • 05/10/22
Ami Bavishi Joins Rallybio to Lead Investor Relations and Corporate CommunicationsBusiness Wire • 01/18/22
Rallybio Highlights Portfolio Advances and Outlines Expected Upcoming Milestones for 2022Business Wire • 01/06/22